Form 4: Dyne Therapeutics Chief Commercial Officer Sells Shares for Tax Obligations

Dyne Therapeutics, Inc.'s Chief Commercial Officer, Johanna Friedl-Naderer, sold 146 shares of common stock at a weighted average price of $13.35 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc. (DYN), reported a sale of common stock.
• The transaction involved the disposition of 146 shares of Dyne Therapeutics common stock on June 5, 2025.
• The shares were sold at a weighted average price of $13.35 per share, with individual sales ranging from $13.21 to $13.46.
• This sale was non-discretionary and automatically executed to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on December 4, 2024.
• Following this transaction, Ms. Friedl-Naderer beneficially owns 95,911 shares of Dyne Therapeutics common stock, which includes 91,476 unvested Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to executive compensation, and does not reflect a change in the executive's investment conviction or the company's operational performance.

Future Outlook

This SEC Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The automatic sale is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1, and does not represent a discretionary trade by the Reporting Person.

Industry Context

This filing is a routine disclosure of an insider transaction, specifically a non-discretionary sale of shares for tax purposes, which is common practice across all industries for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact as this is a small, non-discretionary sale for tax purposes and does not indicate a change in the company's fundamentals or the executive's long-term view.
• Employees: No direct impact beyond the executive involved.

Key Dates

Keywords

Dyne Therapeutics, DYN, SEC Form 4, Insider Transaction, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding, Johanna Friedl-Naderer